X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (75) 75
female (48) 48
male (48) 48
index medicus (44) 44
endocrinology & metabolism (43) 43
middle aged (39) 39
diabetes (34) 34
diabetes mellitus, type 2 - drug therapy (32) 32
aged (28) 28
type 2 diabetes (28) 28
adamantane - analogs & derivatives (26) 26
adult (26) 26
saxagliptin (20) 20
double-blind method (18) 18
dipeptides - adverse effects (17) 17
metformin (17) 17
adamantane - adverse effects (16) 16
adamantane - therapeutic use (16) 16
clinical trials (16) 16
dipeptides - therapeutic use (16) 16
diabetes mellitus, type 2 - complications (15) 15
risk factors (15) 15
care and treatment (14) 14
dosage and administration (14) 14
efficacy (14) 14
animals (13) 13
cardiac & cardiovascular systems (13) 13
mellitus (13) 13
safety (13) 13
transplantation (13) 13
treatment outcome (13) 13
abridged index medicus (12) 12
dipeptidyl-peptidase iv inhibitors - therapeutic use (12) 12
mortality (12) 12
dipeptidyl peptidase-4 inhibitor (11) 11
drug therapy (11) 11
glucose (11) 11
medicine & public health (11) 11
medicine, general & internal (11) 11
adamantane - administration & dosage (10) 10
adolescent (10) 10
aged, 80 and over (10) 10
analysis (10) 10
diabetes mellitus (10) 10
dipeptides - administration & dosage (10) 10
hypoglycemic agents - therapeutic use (10) 10
complications and side effects (9) 9
disease (9) 9
drug therapy, combination (9) 9
heart attacks (9) 9
hypoglycemic agents - adverse effects (9) 9
usage (9) 9
blood glucose - metabolism (8) 8
diabetes mellitus, type 2 - blood (8) 8
dipeptidyl-peptidase iv inhibitors - adverse effects (8) 8
double-blind (8) 8
improves glycemic control (8) 8
internal medicine (8) 8
patient outcomes (8) 8
patients (8) 8
therapy (8) 8
diabetes mellitus, type 1 - surgery (7) 7
events (7) 7
follow-up studies (7) 7
glycemic control (7) 7
hypoglycemia (7) 7
hypoglycemia - chemically induced (7) 7
hypoglycemic agents - administration & dosage (7) 7
cardiovascular disease (6) 6
cardiovascular diseases (6) 6
diabetes mellitus, type 2 - epidemiology (6) 6
glucagon (6) 6
glucose control (6) 6
hospitalization (6) 6
long-term survival (6) 6
management (6) 6
metaanalysis (6) 6
pharmacology & pharmacy (6) 6
research (6) 6
respiratory system (6) 6
retrospective studies (6) 6
risk (6) 6
sitagliptin (6) 6
surgery (6) 6
type-2 (6) 6
type-2 diabetes-mellitus (6) 6
add-on therapy (5) 5
association (5) 5
beta-cell function (5) 5
blood glucose - drug effects (5) 5
cardiovascular diseases - epidemiology (5) 5
diabetes therapy (5) 5
drug administration schedule (5) 5
heart attack (5) 5
heart failure (5) 5
human necessities (5) 5
hygiene (5) 5
immunosuppression (5) 5
inadequate glycemic control (5) 5
incidence (5) 5
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Diabetes Care, ISSN 0149-5992, 05/2004, Volume 27, Issue 5, pp. 1249 - 1251
...The report by Hirshberg et al. (1) describes the National Institutes of Health (NIH) experience in islet-only transplantation using the medical indication... 
Journal Article
Journal Article
Diabetes care, ISSN 1935-5548, 2015, Volume 38, Issue 11, pp. 2009 - 2017
OBJECTIVE To compare the efficacy and safety of treatment with dapagliflozin versus that with placebo add-on to saxagliptin plus metformin in patients whose... 
BODY-WEIGHT | DIPEPTIDYL PEPTIDASE-4 INHIBITOR | SULFONYLUREA | PIOGLITAZONE | EFFICACY | SAFETY | CLINICAL-TRIALS | ENDOCRINOLOGY & METABOLISM | 24-WEEK | MELLITUS | INADEQUATE GLYCEMIC CONTROL | Hypoglycemia - epidemiology | Metformin - therapeutic use | Benzhydryl Compounds - administration & dosage | Humans | Middle Aged | Male | Metformin - adverse effects | Diabetes Mellitus, Type 2 - epidemiology | Benzhydryl Compounds - adverse effects | Hypoglycemic Agents - administration & dosage | Urinary Tract Infections - chemically induced | Adamantane - therapeutic use | Adult | Female | Metformin - administration & dosage | Adamantane - administration & dosage | Hypoglycemia - chemically induced | Glucosides - adverse effects | Adamantane - adverse effects | Adamantane - analogs & derivatives | Hypoglycemic Agents - therapeutic use | Dipeptides - therapeutic use | Double-Blind Method | Dipeptides - adverse effects | Treatment Outcome | Blood Glucose - drug effects | Dipeptides - administration & dosage | Urinary Tract Infections - epidemiology | Drug Therapy, Combination - methods | Glucosides - administration & dosage | Aged | Blood Glucose - metabolism | Diabetes Mellitus, Type 2 - drug therapy | Hypoglycemic Agents - adverse effects | Type 2 diabetes | Treatment outcome | Usage | Safety and security measures | Dapagliflozin | Analysis | Clinical trials | Dosage and administration | Metformin | Saxagliptin
Journal Article
American Heart Journal, ISSN 0002-8703, 2011, Volume 162, Issue 5, pp. 818 - 825.e6
Journal Article
Diabetes care, ISSN 0149-5992, 04/2015, Volume 38, Issue 4, pp. 696 - 705
Journal Article
Circulation (New York, N.Y.), ISSN 1524-4539, 2014, Volume 130, Issue 18, pp. 1579 - 1588
Journal Article
Diabetes care, ISSN 0149-5992, 06/2015, Volume 38, Issue 6, pp. 1145 - 1153
Journal Article
Journal Article
Diabetologia, ISSN 0012-186X, 3/2019, Volume 62, Issue 3, pp. 373 - 386
Cardiovascular disease is the leading cause of morbidity and mortality in people with type 2 diabetes. MEDI4166 is a proprotein convertase subtilisin/kexin... 
Single ascending dose | Human Physiology | Proprotein convertase subtilisin/kexin type 9 antibody | Metabolic Diseases | Internal Medicine | Glucose | Type 2 diabetes mellitus | Multiple ascending dose | Low-density lipoprotein cholesterol | Medicine & Public Health | First-in-human study | Phase 1 | Pharmacokinetics | Glucagon-like peptide-1 analogue | STATEMENT | MANAGEMENT | EFFICACY | SAFETY | Proprotein convertase subtilisin | TREATED PATIENTS | BIOANALYTICAL METHODS VALIDATION | PEPTIDE-1 RECEPTOR AGONISTS | kexin type 9 antibody | LIRAGLUTIDE | ENDOCRINOLOGY & METABOLISM | ASSOCIATION | PRIMARY PREVENTION | Hypoglycemic Agents - therapeutic use | Antibodies - therapeutic use | Overweight - complications | Double-Blind Method | Obesity - drug therapy | Obesity - complications | Overweight - drug therapy | Humans | Middle Aged | Male | Treatment Outcome | Proprotein Convertase 9 - immunology | Female | Diabetes Mellitus, Type 2 - drug therapy | Diabetes Mellitus, Type 2 - complications | Viral antibodies | Type 2 diabetes | Antibodies | Obesity | Headache | Lipoproteins (low density) | Glucagon | Diabetes mellitus | Body weight | Diarrhea | Cardiovascular disease | Subtilisin | Injection | Immunological tolerance | Patients | Low density lipoprotein | Morbidity | Cholesterol | Kexin | Immunogenicity | Diabetes | Cardiovascular diseases | Diabetes mellitus (non-insulin dependent) | Glucagon-like peptide 1 | Drug dosages | Index Medicus
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2013, Volume 369, Issue 14, pp. 1317 - 1326
Saxagliptin, a new oral antihyperglycemic drug in the DPP-4 inhibitor class, had no effect on the risk of cardiovascular events in patients with type 2... 
ALL-CAUSE | MEDICINE, GENERAL & INTERNAL | METAANALYSIS | EVENTS | GLUCOSE CONTROL | MICROALBUMINURIA | DISEASE | CLINICAL-USE | PREVENTION | RISK | DEATH | Dipeptidyl-Peptidase IV Inhibitors - adverse effects | Dipeptidyl-Peptidase IV Inhibitors - therapeutic use | Humans | Middle Aged | Hospitalization - statistics & numerical data | Male | Adamantane - therapeutic use | Aged, 80 and over | Cardiovascular Diseases - epidemiology | Cardiovascular Diseases - mortality | Female | Hypoglycemia - chemically induced | Heart Failure - epidemiology | Diabetes Mellitus, Type 2 - complications | Adamantane - adverse effects | Adamantane - analogs & derivatives | Hypoglycemic Agents - therapeutic use | Cardiovascular Diseases - etiology | Dipeptides - therapeutic use | Double-Blind Method | Pancreatitis - epidemiology | Dipeptides - adverse effects | Kaplan-Meier Estimate | Pancreatitis - chemically induced | Aged | Diabetes Mellitus, Type 2 - drug therapy | Hypoglycemic Agents - adverse effects | Type 2 diabetes | Complications and side effects | Patient outcomes | Dosage and administration | Drug therapy | Heart diseases | Risk factors | Saxagliptin | Myocardial infarction | Cerebral infarction | Heart attacks | Peptidase | Diabetes mellitus | Pancreatitis | Cardiovascular disease | Angina | Patients | Heart rate | Ischemia | Diabetes | Cardiovascular diseases | Diabetes mellitus (non-insulin dependent)
Journal Article
Journal Article